Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 27, 2018

Primary Completion Date

February 2, 2024

Study Completion Date

February 2, 2024

Conditions
Cancer
Interventions
DRUG

Gemcitabine

Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will start at 675 mg/m2/dose. If the MTD has been exceeded at the Dose Level 1, then the subsequent cohort of participants will be treated with gemcitabine at a dose of 500 mg/m2/dose (Dose Level 0).

DRUG

Nab-paclitaxel

Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3).

Trial Locations (4)

30322

Chilldren's Healthcare of Atlanta, Atlanta

33701

Johns Hopkins All Children's Hospital, St. Petersburg

64108

Children's Mercy Hospital, Kansas City

80045

Children's Hospital Colorado, Aurora

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Emory University

OTHER